Lifecore Biomedical (LFCR) Expected to Announce Quarterly Earnings on Friday

Lifecore Biomedical (NASDAQ:LFCR) is expected to announce its Q1 2026 results before the market opens on Friday, October 3rd. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $26.68 million for the quarter. Lifecore Biomedical has set its FY 2026 guidance at EPS.Investors can find conference call details on the company’s upcoming Q1 2026 earningreport page for the latest details on the call scheduled for Friday, October 10, 2025 at 8:30 AM ET.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $36.44 million during the quarter, compared to analyst estimates of $35.36 million. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Performance

NASDAQ LFCR opened at $7.17 on Thursday. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.77 and a current ratio of 2.84. The stock’s fifty day moving average is $7.44 and its two-hundred day moving average is $7.10. The firm has a market capitalization of $268.66 million, a P/E ratio of -5.47 and a beta of 0.62. Lifecore Biomedical has a fifty-two week low of $4.33 and a fifty-two week high of $8.85.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. KeyCorp began coverage on shares of Lifecore Biomedical in a research note on Wednesday, September 3rd. They issued a “sector weight” rating for the company. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.00.

Hedge Funds Weigh In On Lifecore Biomedical

Several institutional investors have recently bought and sold shares of the company. Invesco Ltd. acquired a new stake in Lifecore Biomedical in the 2nd quarter valued at about $3,081,000. Geode Capital Management LLC grew its holdings in Lifecore Biomedical by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 775,493 shares of the company’s stock worth $6,299,000 after acquiring an additional 24,995 shares in the last quarter. Rhumbline Advisers increased its position in shares of Lifecore Biomedical by 54.0% in the 2nd quarter. Rhumbline Advisers now owns 38,091 shares of the company’s stock valued at $309,000 after purchasing an additional 13,361 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Lifecore Biomedical by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 87,998 shares of the company’s stock valued at $620,000 after purchasing an additional 12,647 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Lifecore Biomedical during the 2nd quarter worth $88,000. 83.36% of the stock is owned by institutional investors and hedge funds.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.